InsiderTrades.com logo
Allen S. Melemed net worth and biography
  • Phone
  • Email
  • Website

Allen Melemed Biography and Net Worth

Chief Medical Officer of Chimerix

Dr. Allen Melemed is the Chief Medical Officer at Chimerix.  Dr. Melemed joined Chimerix from Eli Lily where he has spent more than 20 years dedicated to the clinical development and approval of oncology medicines across a broad range of tumor types including VERZENIO®, CYRAMZA®, LARTRUVO®, ALIMTA®  and RETEVMO® among others. Most recently, he served as a Distinguished Medical Fellow and Senior Director of Regulatory Affairs Oncology, North America. In addition to his role at Eli Lilly, Dr. Melemed was an attending physician in pediatric oncology at Indiana University (IU) School of Medicine, Riley Children’s Hospital from 1996 to 2012.

Dr. Melemed holds a B.S. in Genetics and Cell Biology from the University of Minnesota and a M.D. from the University of Minnesota School of Medicine. In addition, he completed his residency in pediatrics at the University of Wisconsin, Madison and fellowship in pediatric hematology/oncology at IU School of Medicine. He earned an M.B.A. from the University of Chicago Booth School of Business. Dr. Melemed has authored dozens of scientific and clinical publications.

What is Allen S. Melemed's net worth?

The estimated net worth of Allen S. Melemed is at least $1.31 million as of February 13th, 2025. Dr. Melemed owns 152,875 shares of Chimerix stock worth more than $1,305,553 as of May 1st. This net worth evaluation does not reflect any other assets that Dr. Melemed may own. Additionally, Dr. Melemed receives an annual salary of $665,500.00 as Chief Medical Officer at Chimerix. Learn More about Allen S. Melemed's net worth.

How old is Allen S. Melemed?

Dr. Melemed is currently 60 years old. There are 5 older executives and no younger executives at Chimerix. Learn More on Allen S. Melemed's age.

What is Allen S. Melemed's salary?

As the Chief Medical Officer of Chimerix, Inc., Dr. Melemed earns $665,500.00 per year. The highest earning executive at Chimerix is Mr. Michael T. Andriole M.B.A., CEO, President & Director, who commands a salary of $820,000.00 per year. Learn More on Allen S. Melemed's salary.

How do I contact Allen S. Melemed?

The corporate mailing address for Dr. Melemed and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at ir@chimerix.com. Learn More on Allen S. Melemed's contact information.

Has Allen S. Melemed been buying or selling shares of Chimerix?

Allen S. Melemed has not been actively trading shares of Chimerix during the last ninety days. Most recently, Allen S. Melemed sold 3,065 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.50, for a transaction totalling $13,792.50. Following the completion of the sale, the insider now directly owns 152,875 shares of the company's stock, valued at $687,937.50. Learn More on Allen S. Melemed's trading history.

Who are Chimerix's active insiders?

Chimerix's insider roster includes Michael Alrutz (Senior Vice President and General Counsel), Michael Andriole (President, CEO, and Director), Martha Demski (Director), David Jakeman (Insider), Michelle LaSpaluto (Chief Financial Officer), Allen Melemed (Chief Medical Officer), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.

Are insiders buying or selling shares of Chimerix?

In the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 22,045 shares worth more than $92,241.70. The most recent insider tranaction occured on February, 13th when insider Allen S Melemed sold 3,065 shares worth more than $13,792.50. Insiders at Chimerix own 13.1% of the company. Learn More about insider trades at Chimerix.

Information on this page was last updated on 2/13/2025.

Allen S. Melemed Insider Trading History at Chimerix

See Full Table

Allen S. Melemed Buying and Selling Activity at Chimerix

This chart shows Allen S Melemed's buying and selling at Chimerix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10k-$5k$0$5k$10kTotal Insider BuyingTotal Insider Selling

Chimerix Company Overview

Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.54
Low: $8.54
High: $8.54

50 Day Range

MA: $8.00
Low: $4.60
High: $8.55

2 Week Range

Now: $8.54
Low: $0.75
High: $8.55

Volume

N/A

Average Volume

2,301,331 shs

Market Capitalization

$801.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A